Compare GE Vernova Inc (GEV) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Nuwellis Inc — how do they compare? GE Vernova Inc trades at $998.78 (market cap $266.16B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: GE Vernova Inc is far larger — about 120981.8× Nuwellis Inc's market cap, and GE Vernova Inc pays a 0.2% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Nuwellis Inc for 26 Days on average.
| GEV | NUWE | |
|---|---|---|
Market Cap | $266.16B | $2.20M |
Volume | 2,324,165 | 121,544 |
Sector | Industrials | Health |
52-Week High | $1.17K | $146.65 |
52-Week Low | $547.96 | $0.68 |
Typical Hold Time | 36 Days | 26 Days |
Enterprise Value | $255.83B | -$1.52M |
Dividend Yield | 0.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $986.62, down 1.05% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical momentum with support at $973 and resistance at $1,026. Recent Q1 2026 earnings beat expectations with EPS of $17.44 versus $1.95 expected, while Q2 2026 missed estimates. The company secured the first US construction permit for its BWRX-300 small modular reactor, strengthening its nuclear pipeline amid growing AI-driven power demand.
Outlook remains positive with projected revenue growth to $41.4B in 2026 and net profit margin expanding to 23.03%. Key risks include valuation concerns with P/E of 28.65 and EV/EBITDA of 85.22, plus execution challenges in scaling nuclear projects. The stock offers exposure to AI infrastructure growth but requires monitoring of margin expansion and backlog conversion.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
